Last reviewed · How we verify
Brimonidine Topical
At a glance
| Generic name | Brimonidine Topical |
|---|---|
| Also known as | Alphagan |
| Sponsor | University of Louisville |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
- Brimonidine 0.33% for Rosacea-Related Facial Erythema (PHASE4)
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE3)
- A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness (PHASE3)
- Brimonidine for Intraoperative Hemostasis (PHASE4)
- Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia (PHASE3)
- Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia (PHASE1)
- Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine Topical CI brief — competitive landscape report
- Brimonidine Topical updates RSS · CI watch RSS
- University of Louisville portfolio CI